12月17日上午，常州市财政局召开新闻发布会，通报2025年常州市财政运行情况。面对复杂严峻的外部 环境，常州经济展现出了令人瞩目的韧性。一系列财政关键指标不仅勾勒出"稳"的基调，更折射 出"进"的动能与"新"的活力。2025年度常州财政收入在量级上实现关键跨越，支出结构持续优化向民， 深层次的财政管理与服务创新，正为这座城市的高质量发展注入源源不断的财政智慧与力量。 关键跃升：收入突破700亿大关，质量全省领跑 服务升级："免申即享"让惠企利民政策精准直达 政府"过紧日子"，是为了让老百姓"过好日子"。1-11月，常州市一般公共预算支出677亿元，其中用于 教育、社保、医疗、住房等民生领域的支出达527.4亿元，占比高达78%。每一分钱都力求花在刀刃 上，转化为百姓实实在在的获得感：新增老年助餐点服务老年人超518万人次，省市级普惠托育机构达 99家，城乡低保等标准稳步提升……一套覆盖"一老一小"、就业增收、社会保障的民生网络越织越密。 这笔"民生账"的可持续，源于财政管理的"效能账"。今年，常州在省内率先深化零基预算改革，试 点"业财协同"新机制。"我们改变了以往业务部门'报项目'、财政部门'砍预算'的传 ...

12月17日上午，常州市财政局召开新闻发布会，通报2025年常州市财政运行情况。面对复杂严峻的外部 环境，常州经济展现出了令人瞩目的韧性。一系列财政关键指标不仅勾勒出"稳"的基调，更折射 出"进"的动能与"新"的活力。2025年度常州财政收入在量级上实现关键跨越，支出结构持续优化向民， 深层次的财政管理与服务创新，正为这座城市的高质量发展注入源源不断的财政智慧与力量。 关键跃升：收入突破700亿大关，质量全省领跑 数字是发展最直观的注脚。2025年1-11月，常州市一般公共预算收入完成671.5亿元，同比增长2.7%， 增幅呈现逐季稳步上扬的曲线。尤为亮眼的是收入质量：税收收入增长4.3%，税收占比高达86%，这一 反映经济效益的核心指标持续稳居全省首位。根据研判，全年收入预计将历史性地突破700亿元大关， 完成从稳步积累到能级跃升的关键一步。 政府"过紧日子"，是为了让老百姓"过好日子"。1-11月，常州市一般公共预算支出677亿元，其中用于 教育、社保、医疗、住房等民生领域的支出达527.4亿元，占比高达78%。每一分钱都力求花在刀刃 上，转化为百姓实实在在的获得感：新增老年助餐点服务老年人超518万人次 ...

即将过去的2025年，科技产业历经诸多变革，助推科技股成为贯穿全年的行情主线。年末之际，人工智能、芯片、新能源等科技主题的行情波动明显放 大。随着AI泡沫之争再起，新一年的科技投资脉络成为市场关注焦点。 迷雾之中，长城基金2026年度投资策略会如约而至。赵凤飞、尤国梁、梁福睿、龙宇飞、韩林、刘疆等多位深耕"科技+"领域的基金经理，聚焦科技投资 领域的热门问题展开深度探讨。 以下为本次策略会中长城基金"科技+"基金经理分享的部分精彩观点： 赵凤飞：2026年的市场风格将更加均衡：一是算力板块内海外与国产算力趋向均衡，二是AI领域内算力与应用趋向均衡，三是科技板块内AI与商业航 天、量子计算等非AI赛道趋向均衡。 尤国梁：前不久的可回收火箭发射相当于商业航天产业的"成人礼"，直接为卫星互联网、太空算力、6G等未来赛道铺好了运力底座，一个全新的万亿级 市场正在被打开。 梁福睿：面对国内集采、海外药价管控带来的全球医药通缩压力，只有具备全球化能力、能迭代现有治疗方式的创新药与器械企业，才能突破发展瓶颈。 龙宇飞：医药行业核心竞争力标准持续演进：十几年前比拼商业化能力，5-10年前转向产品研发与产品力，如今则要求研发与 ...

Core Viewpoint - The trend of "introduction listing" is gaining popularity among companies in the Hong Kong stock market, allowing them to list without raising new funds, thus streamlining the process and reducing costs [2][8]. Group 1: Reasons for Choosing "Introduction Listing" - "Introduction listing" allows companies to list their existing shares on the exchange without issuing new stocks or raising funds, making it a more efficient process that can be completed in 3 to 6 months [2]. - This method is particularly suitable for companies seeking dual listings, such as those already listed on foreign exchanges, to expand their shareholder base and attract regional investors [2]. - Companies planning to transition from the Hong Kong Growth Enterprise Market to the main board can also utilize this method to enhance market credibility and liquidity without the need for new stock issuance [3]. - Subsidiaries or restructured entities with a mature shareholder structure can directly list their shares, as they already have a distribution base that meets market liquidity requirements [4]. Group 2: Strategic Value Analysis of Companies - Dongyang Sunshine Pharmaceutical became the first case of H-share absorption merger and introduction listing in Hong Kong, allowing it to lower integration costs and time without issuing new shares [5]. - Lantu Motors is pursuing an "introduction listing + privatization" strategy, where it will first distribute shares to existing shareholders before listing, facilitating access to capital markets while optimizing asset value for its parent company [6]. - Xin'ao Holdings plans to achieve a dual listing through privatization, aiming to create a closed-loop natural gas industry chain and enhance resource synergy and capital operation capabilities [7]. Group 3: Importance of Introduction Listing in Capital Strategy - Introduction listing is becoming a crucial part of corporate capital strategies, representing a shift from the traditional view of listing as a means to raise funds [8]. - This approach enables companies to quickly enter the capital market, achieve valuation restructuring, industry integration, and brand upgrading, laying the groundwork for future financing and business expansion [8].

Group 1: Monetary Policy and Economic Outlook - The monetary policy in 2026 will continue to align with fiscal measures, supporting debt sustainability and fiscal health [2] - Interest rate cuts in 2026 may remain restrained due to reduced urgency from anti-involution trends [2] - The international economic struggle will have financial implications, particularly for the internationalization of the RMB amid intensified US-China tensions [2][13] Group 2: Misunderstandings about "Deposit Migration" - There are three main misunderstandings regarding "deposit migration": underestimating excess savings, the speed of market entry, and the investment attributes of excess savings [3][15] - The potential scale of household savings entering the stock market could exceed one trillion yuan, driven by a significant increase in excess savings [3][15] - The speed of funds entering the market may be underestimated due to reliance on non-bank deposit tracking, which does not accurately reflect the migration of household funds [3][15] Group 3: Huahai Pharmaceutical (600521) Insights - Huahai Pharmaceutical integrates raw materials and formulations, establishing a solid foundation for growth, with a projected revenue of 5.759 billion yuan in 2024 [4][14] - The company is focusing on innovative drug development in immunology and oncology, with over 70 patents filed and several projects in clinical stages [4][18] - The target market capitalization for Huahai Pharmaceutical is estimated at 34.4 billion yuan, indicating a potential upside of 30.04% [4][18] Group 4: Zhongxin Innovation (03931) Overview - Zhongxin Innovation is positioned to benefit from the growing demand for energy storage and electric vehicle batteries, with a revenue of 16.4 billion yuan in the first half of 2025 [19][20] - The company is expanding its market share and enhancing its product offerings, with a focus on high-end battery products and a global production network [19][20] - The projected net profit for Zhongxin Innovation is expected to grow significantly, reaching 3.84 billion yuan by 2027 [20]

Core Insights - The collaboration between Jiuzhoutong and Haizheng Pharmaceutical aims to reshape the retail channel competition in the pharmaceutical industry through a strategic partnership focused on complementary strengths in "industry + channel" [1][2] Group 1: Strategic Partnership - Jiuzhoutong's subsidiary, All-Qing Health, has signed a strategic cooperation agreement with Haizheng Pharmaceutical, becoming the exclusive agent responsible for the retail promotion of several core products, with an initial cooperation value exceeding 400 million yuan [1][2] - The partnership is expected to enhance both companies' performance and reflects a deeper transformation in the professional division of labor within the pharmaceutical industry [1][3] Group 2: Business Performance - Jiuzhoutong has been implementing its "Three New and Two Transformations" strategy since 2025, optimizing its business structure and improving operational efficiency, resulting in steady growth across its main business segments [1][4] - In the first three quarters of 2025, Jiuzhoutong achieved revenue of 119.33 billion yuan, a year-on-year increase of 5.20%, and a net profit of 1.975 billion yuan, up 16.46% [4][5] Group 3: Product Strategy - The new product strategy is a key component of Jiuzhoutong's growth, focusing on integrating resources to form a new product business organization matrix centered around CSO, which includes All-Qing Health and other subsidiaries [4][5] - Jiuzhoutong's CSO business generated sales revenue of 14.728 billion yuan in the first three quarters, with a significant contribution from core products like Kewai and Miko Bao, which saw a 15.26% increase in sales [5][6] Group 4: Market Expansion - The collaboration is expected to inject new vitality into the domestic pharmaceutical retail market, with plans for deep cooperation in global expansion, all-channel operations, and capital linkage [3][4] - The initial product offerings include key medications with strong market demand, and the retail sales scale is projected to double by 2026 [3][4]

Macro Insights - The internal economic momentum is weakening, and the policy window is gradually approaching, with a focus on stabilizing consumption and investment through counter-cyclical policies [2] - The "pig cycle" investment paradigm is shifting, with supply reduction in the pig industry driven by profit losses and policy adjustments, but the elasticity of pig prices is expected to be weaker than in previous cycles [3] - The healthcare negotiations in the U.S. are becoming a political tool, with significant implications for the capital markets, as budget agreements remain unresolved [4] Bond Market Analysis - Major economic indicators have further declined, with industrial production growth slowing year-on-year, while fixed asset investment shows an expanding decline [6] - The bond market is currently experiencing a relatively loose funding environment, and investors are advised to adopt a gradually optimistic outlook, with a forecast for the 10-year government bond yield to stabilize around 1.75% [6][5] Real Estate Sector - In the real estate market, new home transactions in 20 cities totaled 735,000 units, down 14.8%, with significant declines in cities like Beijing and Shenzhen [7] - The second-hand housing market showed a slight increase in transactions, with a total of 725,000 units sold, indicating a mixed performance across major cities [7] Company Research - Zhaoli Pharmaceutical is set to acquire a range of trace element injection assets, which will enhance its product structure and leverage synergies, with a favorable market outlook for these products [9] - The acquisition is expected to significantly boost the company's revenue and profit, with projected net profits for 2025-2027 at 655 million, 836 million, and 1.063 billion yuan, respectively, corresponding to PE ratios of 18, 14, and 11 times [9]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002168 证券简称：*ST惠程 公告编号：2025－097 一、召开会议的基本情况 1.股东会届次：2025年第五次临时股东会 2.股东会的召集人：公司董事会 3.本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门规章、规范 性文件及《公司章程》的有关规定。 4.会议时间： （1）现场会议时间：2025年12月31日14：30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2025年12月31日9：15-9： 25，9：30-11：30，13：00-15：00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年12 月31日9：15至15：00的任意时间。 5.会议的召开方式：现场表决与网络投票相结合。 重庆惠程信息科技股份有限公司 关于召开2025年第五次临时股东会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗 漏。 6.会议的股权登记日：2025 ...

Summary of Key Points Overall Perspective - The report highlights that social financing (社融) increased by 2.49 trillion yuan in November 2025, exceeding market expectations, with a year-on-year growth of 8.5% in social financing stock, remaining stable compared to the previous value [7][8] - The report indicates a structural differentiation in credit data, with traditional industries like real estate and infrastructure showing a decline in credit demand, while emerging industries are less reliant on bank loans [9] Industry Insights Electronics - The semiconductor equipment sector is identified as a key technology line with strong certainty and elasticity, with the semiconductor index rising by 3.30% [14] - The report notes that major overseas tech companies have underperformed, leading to a significant drop in the Philadelphia Semiconductor Index by 3.58% [14] Retail - The retail sales in November 2025 showed a year-on-year increase of 1.3%, with total retail sales amounting to 4.569 trillion yuan from January to November, reflecting a 4.0% increase year-on-year [19][20] - The report emphasizes the resilience of essential goods like grain and oil, while discretionary categories like jewelry performed relatively well [20] Real Estate - New home prices in November 2025 showed a reduced decline, with first-tier cities experiencing a larger drop compared to second and third-tier cities [24][25] - The report suggests that the real estate market is moving towards stabilization, supported by various policies aimed at preventing further declines [28] Media - The gaming sector is expected to see increased activity due to the upcoming holiday season, with new game releases anticipated to boost revenue [30] - The report highlights the collaboration between Disney and OpenAI, which is expected to enhance the value of content IP [31][33] Pharmaceuticals - The report discusses the acquisition of a multi-element injection asset group by Zuo Li Pharmaceutical, which is expected to enrich its product structure and enhance marketing synergy [43][44] - The market for multi-element injections is projected to reach approximately 1.8 billion yuan by 2024, with continued growth expected [44] Military Industry - Hua Qin Technology is positioned to benefit from the increasing demand for stealth materials due to the accelerated deployment of new stealth aircraft [48][49] - The company is also expanding into high-value areas related to aircraft engines, which is expected to create a second growth curve [50] Power Equipment and New Energy - Tian Ci Materials is recognized as a global leader in lithium hexafluorophosphate and electrolyte production, with a projected global market share of 35.7% in 2024 [51]

Core Viewpoint - The National Medical Security Work Conference held in December 2025 emphasizes the optimization of centralized procurement policies, the development of maternity and long-term care insurance, and the strategic purchasing role of medical insurance to support the innovative drug industry [1][2]. Group 1: Support for Commercial Health Insurance - The National Medical Security Bureau will support the integration and complementary development of commercial health insurance with basic medical insurance, encouraging the inclusion of more reasonable medical expenses outside the basic medical insurance catalog into the coverage of commercial health insurance [2]. - There will be an encouragement for commercial health insurance institutions to expand their investment in innovative drugs, promoting research and development in this area [2]. - A one-stop settlement service combining "medical insurance + commercial insurance" will be provided for eligible commercial health insurance products, aimed at improving claims efficiency [2]. Group 2: Development of Maternity and Long-term Care Insurance - The National Medical Security Bureau aims to include flexible employment personnel, migrant workers, and new employment forms in the coverage of maternity insurance [2]. - The goal is to achieve "no out-of-pocket" expenses for childbirth within the policy scope nationwide, with enhancements to prenatal examination medical expense coverage [2]. - The long-term care insurance system will be comprehensively promoted, with encouragement for commercial insurance institutions to develop commercial long-term care insurance products [2]. Group 3: Support for Pharmaceutical Industry Innovation - The National Medical Security Bureau will guide the pharmaceutical industry towards healthy competition and differentiated innovation, implementing measures to support the high-quality development of innovative drugs [3]. - New rounds of national centralized procurement for drugs and high-value medical consumables will be conducted, with a focus on improving the efficiency of enterprise returns [3]. - The multi-price discovery function of the Chinese drug price registration system will be leveraged to assist the Chinese pharmaceutical industry in expanding internationally [3].